Ignite Creation Date:
2025-12-24 @ 2:08 PM
Ignite Modification Date:
2026-02-19 @ 11:51 AM
Study NCT ID:
NCT05809895
Status:
WITHDRAWN
Last Update Posted:
2023-07-24
First Post:
2023-03-30
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer
Sponsor:
Novartis Pharmaceuticals
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Triple Negative Breast Cancer | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | TNBC | View |
| None | Triple Negative Breast Cancer | View |
| None | PD-L1 | View |
| None | Ociperlimab | View |
| None | Tislelizumab | View |
| None | WCD118 (BGB-A1217) | View |
| None | VDT482 (BGB-A317) | View |
| None | Pembrolizumab | View |
| None | Carboplatin | View |
| None | Gemcitabine | View |
| None | Paclitaxel | View |
| None | Nab-paclitaxel | View |
| None | TIGIT | View |
| None | Combination immunotherapy | View |